Dermata Therapeutics Set to Introduce First Over-the-Counter Acne Kit by Mid-2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Should l Buy DRMA?
Source: NASDAQ.COM
Company Milestone: Dermata Therapeutics Inc. is set to launch its first over-the-counter acne kit in mid-2026, utilizing its proprietary Spongilla technology, which has shown clinical efficacy in treating moderate-to-severe acne.
Technology Overview: The Spongilla technology, derived from freshwater sponges, features microscopic spicules that penetrate the skin to deliver active ingredients, unclog pores, and promote exfoliation.
Market Strategy: The company plans to market the acne kit directly to consumers, estheticians, and dermatologists, aiming to establish a strong brand identity for its OTC dermatology portfolio.
Financial Status: As of September 30, 2025, Dermata had $4.7 million in cash, expected to support operations through the second quarter of 2026, while its stock has fluctuated between $2.34 and $23.70 over the past year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DRMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DRMA
Wall Street analysts forecast DRMA stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.140
Low
10.00
Averages
10.00
High
10.00
Current: 1.140
Low
10.00
Averages
10.00
High
10.00
About DRMA
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dermata Therapeutics Reports Increased Losses in FY Earnings
- Financial Performance: Dermata Therapeutics reported a FY GAAP EPS of -$8.16, indicating a continued loss that highlights significant challenges to the company's profitability.
- Cash Position: As of December 31, 2025, the company had $7.5 million in cash and cash equivalents, up from $3.2 million in 2024, reflecting a $4.3 million increase that suggests some progress in financial stability.
- Financing Activities: In 2025, the company generated approximately $12.1 million in net financing proceeds, although $7.8 million was used in operations, indicating that financing activities provided essential liquidity support despite operational cash burn.
- Operational Funding Outlook: The company expects its current cash resources to be sufficient to fund operations into the first quarter of 2027, demonstrating short-term financial stability, yet long-term profitability remains a concern.
See More
Comfort Systems Reports Strong Earnings Beat
- Earnings Beat: Comfort Systems reported earnings of $9.37 per share, surpassing the analyst consensus estimate of $6.75, indicating a significant improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $2.646 billion, exceeding the analyst consensus estimate of $2.337 billion, reflecting strong market demand and driving overall performance.
- Positive Stock Reaction: Comfort Systems shares jumped 4.6% to $1,436.25 in pre-market trading, indicating a favorable market response to the earnings report, which may attract more investor interest.
- Optimistic Market Outlook: The strong earnings data not only enhances the company's short-term stock price but also lays the groundwork for future growth, increasing market attractiveness for long-term investments in Comfort Systems.
See More
OceanFirst Financial Corp. Announces $579 Million All-Stock Acquisition of Flushing, Shares Drop 7.4%
- Acquisition Announcement: OceanFirst Financial Corp. has announced a $579 million all-stock acquisition of Flushing Financial, which aims to enhance market share, yet the stock price fell 7.4%, indicating a negative market reaction to the deal.
- Market Reaction: Following the acquisition news, OceanFirst's shares dropped to $18.15, reflecting investor uncertainty regarding integration risks and potential returns, which may impact the company's short-term capital flow.
- Strategic Implications: This acquisition represents OceanFirst's strategic move to expand its presence in the New Jersey market, potentially increasing its customer base and long-term profitability, although short-term stock volatility may undermine investor confidence.
- Investor Focus: As the acquisition progresses, the market will closely monitor how OceanFirst manages the integration process and its impact on financial performance, especially in the current economic climate where investors are cautious about the banking sector.
See More
Fonar Corp (FONR) Signs Definitive Agreement for Take-Private Sale, Shares Surge 24.5%
- Take-Private Agreement Signed: Fonar Corp announced the signing of a definitive agreement for a take-private sale, resulting in a 24.5% surge in pre-market shares to $18.25, indicating strong market confidence that could provide financial backing for future growth.
- Strong Market Reaction: The stock's robust performance in pre-market trading reflects optimistic investor sentiment regarding the privatization deal, potentially attracting more investor interest and enhancing the company's overall market capitalization.
- Significant Industry Impact: Fonar's privatization move may trigger similar actions among other medical device companies, prompting more firms in the sector to consider privatization to enhance operational efficiency and shareholder value.
- Future Strategic Direction: By going private, Fonar is expected to concentrate resources on its core business and optimize its operational model, thereby strengthening its market position and profitability in a highly competitive healthcare market.
See More
TEN Holdings Inc. Announces $2.25 Million Private Placement, Shares Surge 16.31%
- Private Placement: TEN Holdings Inc. announced a $2.25 million private placement of 991,000 shares at $2.27 per share, resulting in a 16.31% surge in stock price, indicating strong market confidence in its financing strategy.
- Market Performance: Despite a weaker price trend in the short term, this financing could provide essential capital support, enhancing the company's operational capabilities and competitive edge in the market.
- Industry Impact: The financing initiative by TEN Holdings is particularly significant in the current economic climate, especially as investor interest in emerging markets rises, potentially attracting more attention from investors.
- Strategic Outlook: Through this private placement, TEN Holdings not only improves its capital structure but also lays the groundwork for future expansion and innovation, thereby enhancing its position within the industry.
See More
TEN Holdings Inc. Raises $2.25M in Private Placement, Shares Surge 17%
- Successful Private Placement: TEN Holdings Inc. announced a private placement of 991,000 shares at $2.27 each, raising $2.25 million, with shares climbing 17% to $1.65 in after-hours trading, indicating strong market confidence in its financing strategy.
- Acquisition Agreement Signed: Fonar Corp. revealed it has signed a definitive agreement for a “take private” sale, resulting in a 24% surge in shares to $18.18 in after-hours trading, reflecting investor optimism regarding the company's privatization prospects.
- FDA Application Submitted: CapsoVision Inc. submitted its 510(k) application for its proprietary AI-assisted module to the FDA, although shares dipped 11% to $11.58 on Monday, this development may pave the way for future market access.
- Clinical Study Discontinuation: Verastem Inc. announced the discontinuation of its RAMP 203 clinical study, leading to a 2.7% drop in shares to $7.55 in after-hours trading, highlighting market concerns over its clinical progress.
See More
Dermata Therapeutics Reports Increased Losses in FY Earnings
- Financial Performance: Dermata Therapeutics reported a FY GAAP EPS of -$8.16, indicating a continued loss that highlights significant challenges to the company's profitability.
- Cash Position: As of December 31, 2025, the company had $7.5 million in cash and cash equivalents, up from $3.2 million in 2024, reflecting a $4.3 million increase that suggests some progress in financial stability.
- Financing Activities: In 2025, the company generated approximately $12.1 million in net financing proceeds, although $7.8 million was used in operations, indicating that financing activities provided essential liquidity support despite operational cash burn.
- Operational Funding Outlook: The company expects its current cash resources to be sufficient to fund operations into the first quarter of 2027, demonstrating short-term financial stability, yet long-term profitability remains a concern.
See More
Comfort Systems Reports Strong Earnings Beat
- Earnings Beat: Comfort Systems reported earnings of $9.37 per share, surpassing the analyst consensus estimate of $6.75, indicating a significant improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $2.646 billion, exceeding the analyst consensus estimate of $2.337 billion, reflecting strong market demand and driving overall performance.
- Positive Stock Reaction: Comfort Systems shares jumped 4.6% to $1,436.25 in pre-market trading, indicating a favorable market response to the earnings report, which may attract more investor interest.
- Optimistic Market Outlook: The strong earnings data not only enhances the company's short-term stock price but also lays the groundwork for future growth, increasing market attractiveness for long-term investments in Comfort Systems.
See More
OceanFirst Financial Corp. Announces $579 Million All-Stock Acquisition of Flushing, Shares Drop 7.4%
- Acquisition Announcement: OceanFirst Financial Corp. has announced a $579 million all-stock acquisition of Flushing Financial, which aims to enhance market share, yet the stock price fell 7.4%, indicating a negative market reaction to the deal.
- Market Reaction: Following the acquisition news, OceanFirst's shares dropped to $18.15, reflecting investor uncertainty regarding integration risks and potential returns, which may impact the company's short-term capital flow.
- Strategic Implications: This acquisition represents OceanFirst's strategic move to expand its presence in the New Jersey market, potentially increasing its customer base and long-term profitability, although short-term stock volatility may undermine investor confidence.
- Investor Focus: As the acquisition progresses, the market will closely monitor how OceanFirst manages the integration process and its impact on financial performance, especially in the current economic climate where investors are cautious about the banking sector.
See More
Fonar Corp (FONR) Signs Definitive Agreement for Take-Private Sale, Shares Surge 24.5%
- Take-Private Agreement Signed: Fonar Corp announced the signing of a definitive agreement for a take-private sale, resulting in a 24.5% surge in pre-market shares to $18.25, indicating strong market confidence that could provide financial backing for future growth.
- Strong Market Reaction: The stock's robust performance in pre-market trading reflects optimistic investor sentiment regarding the privatization deal, potentially attracting more investor interest and enhancing the company's overall market capitalization.
- Significant Industry Impact: Fonar's privatization move may trigger similar actions among other medical device companies, prompting more firms in the sector to consider privatization to enhance operational efficiency and shareholder value.
- Future Strategic Direction: By going private, Fonar is expected to concentrate resources on its core business and optimize its operational model, thereby strengthening its market position and profitability in a highly competitive healthcare market.
See More
TEN Holdings Inc. Announces $2.25 Million Private Placement, Shares Surge 16.31%
- Private Placement: TEN Holdings Inc. announced a $2.25 million private placement of 991,000 shares at $2.27 per share, resulting in a 16.31% surge in stock price, indicating strong market confidence in its financing strategy.
- Market Performance: Despite a weaker price trend in the short term, this financing could provide essential capital support, enhancing the company's operational capabilities and competitive edge in the market.
- Industry Impact: The financing initiative by TEN Holdings is particularly significant in the current economic climate, especially as investor interest in emerging markets rises, potentially attracting more attention from investors.
- Strategic Outlook: Through this private placement, TEN Holdings not only improves its capital structure but also lays the groundwork for future expansion and innovation, thereby enhancing its position within the industry.
See More
TEN Holdings Inc. Raises $2.25M in Private Placement, Shares Surge 17%
- Successful Private Placement: TEN Holdings Inc. announced a private placement of 991,000 shares at $2.27 each, raising $2.25 million, with shares climbing 17% to $1.65 in after-hours trading, indicating strong market confidence in its financing strategy.
- Acquisition Agreement Signed: Fonar Corp. revealed it has signed a definitive agreement for a “take private” sale, resulting in a 24% surge in shares to $18.18 in after-hours trading, reflecting investor optimism regarding the company's privatization prospects.
- FDA Application Submitted: CapsoVision Inc. submitted its 510(k) application for its proprietary AI-assisted module to the FDA, although shares dipped 11% to $11.58 on Monday, this development may pave the way for future market access.
- Clinical Study Discontinuation: Verastem Inc. announced the discontinuation of its RAMP 203 clinical study, leading to a 2.7% drop in shares to $7.55 in after-hours trading, highlighting market concerns over its clinical progress.
See More
